Only 0.8 percent of 483 patients with mild-to-moderate SARS-CoV-2 at high risk for severe disease progression had rebound<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, June 16, 2022 (HealthDay News) — Few patients experience rebound of COVID-19 symptoms after nirmatrelvir\/ritonavir (NM\/R) treatment, according to research published online June 14 in Clinical Infectious Diseases.<\/em><\/p>\n Nischal Ranganath, M.D., Ph.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a retrospective review among patients who received NM\/R treatment for mild-to-moderate severe acute respiratory syndrome coronavirus 2. Data were included for 483 patients (median age, 63 years) who had a high risk for severe disease progression. Overall, 93 percent of the patients were fully vaccinated. <\/p>\n The researchers found that four of the patients (0.8 percent) experienced symptom rebound, defined as recurrence of COVID-19 symptoms following successful completion of five days of NM\/R therapy, at a median of nine days after NM\/R treatment. All four were fully vaccinated. None of the patients required hospitalization, and all improved without further treatment.<\/p>\n “Rebound after NM\/R treatment is uncommon in our population of high-risk, but mostly nonimmunocompromised [patients],” the authors write. “Among the patients who developed rebound of symptoms after NM\/R treatment, the clinical presentation was mild and did not require COVID-19 directed therapies.”<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n